Blood TCRs go to town with early NPC detection

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-07-10 DOI:10.1016/j.ccell.2025.06.016

Shin-Heng Chiou, Diane Tseng

引用次数: 0

Abstract

In this issue of Cancer Cell, Zhang et al. report an innovative approach utilizing patients’ blood T cell receptor (TCR) sequences for the early detection of nasopharyngeal cancer. This study highlights the potential of harnessing highly public TCRs in the peripheral blood as biomarkers for virally associated malignancies.

查看原文本刊更多论文

血tcr去城镇与早期的NPC检测

在这一期的Cancer Cell中，Zhang等人报道了一种利用患者血液T细胞受体（TCR）序列进行鼻咽癌早期检测的创新方法。这项研究强调了利用外周血中高度公开的tcr作为病毒相关恶性肿瘤的生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.